Company Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer.
It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer.
It is also developing NUC-7738, a ProTide transformation of 3’-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors.
The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates.
The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
| Country | United Kingdom |
| Founded | 1997 |
| IPO Date | Sep 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Hugh Griffith |
Contact Details
Address: 3 Lochside Way Edinburgh, EH12 9DT United Kingdom | |
| Phone | 44 13 1357 1111 |
| Website | nucana.com |
Stock Details
| Ticker Symbol | NCNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| CIK Code | 0001709626 |
| CUSIP Number | 67022C106 |
| ISIN Number | US67022C1062 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hugh Stephen Griffith | Founder, Chief Executive Officer and Executive Director |
| David Harrison | Head of Translational Medicine and Studies |
| Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. | Chief Medical Officer |
| Theresa Bruce | Senior Vice President of Clinical Operations |
| Elisabeth Oelmann | Senior Vice President of Medical and Clinical Development |
| Gordon Kennovin | Senior Vice President of CMC and Development |
| Dr. Stuart Grant | Senior Vice President of Regulatory Affairs |
| Martin Alexander Quinn | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | 424B4 | Prospectus |
| May 5, 2025 | EFFECT | Notice of Effectiveness |
| May 5, 2025 | EFFECT | Notice of Effectiveness |
| May 2, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Apr 29, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Apr 24, 2025 | F-6 | Filing |
| Apr 24, 2025 | F-1 | Registration statement for certain foreign private issuers |
| Apr 23, 2025 | 6-K | Report of foreign issuer |
| Apr 18, 2025 | SCHEDULE 13D/A | Filing |
| Apr 4, 2025 | DRS | [Cover] Draft Registration Statement |